Filgrastim 41 Peripheral blood stem 36 total No significant differences in the III-3 B B (Zarzio) cell (PBSC) mobilisation collection of the optimal cell (retrospective) in healthy matched dose 18 Zarzio donors for allogeneic 3/18 (16.6%) donors that 18 Neupogen stem cell transplantation received Zarzio failed to (allo-HSCT) mobilise the optimal cell dose compared with 0% in the Neupogen group Platelet and neutrophil median time to engraftment was comparable between the two groups
Filgrastim (Zarzio) 41 Peripheral blood stem cell (PBSC) mobilisation in healthy matched donors for allogeneic stem cell transplantation (allo-HSCT) 36 total 18 Zarzio 18 Neupogen No significant differences in the collection of the optimal cell dose 3/18 (16.6%) donors that received Zarzio failed to mobilise the optimal cell dose compared with 0% in the Neupogen group Platelet and neutrophil median time to engraftment was comparable between the two groups III-3 (retrospective) B B
biosimilars-literature-review-report.docx